Albert Seymour, Ph.D., serves as the President and Chief Executive Officer of Homology Medicines and previously served as Chief Scientific Officer. Dr. Seymour has spent more than 20 years coupling the discipline of human genetics with pharmaceutical R&D, resulting in the delivery of multiple therapeutic programs into development. At Homology, Dr. Seymour is responsible for translating the Company’s in vivo AAVHSC platform into treatments for rare disorders. Through his leadership, Homology’s phenylketonuria (PKU) program advanced from scientific concept to the world’s first gene therapy clinical trial for PKU in just under three years, in addition to building a pipeline of genetic medicine programs in late stage preclinical development. Prior to Homology, Dr. Seymour was the Senior Vice President and Global Head of Research and Nonclinical Development at Shire, where he led a team responsible for the delivery of a sustained flow of rare disease therapeutics from idea to IND and supported the full R&D portfolio in the areas of toxicology, bioanalytics and Drug Metabolism and Pharmacokinetics. Prior to that role, Dr. Seymour served as the VP and Head of Drug Discovery and Translational Research at Shire, where he doubled the rare disease discovery portfolio in three years. Before joining Shire, he spent 14 years at Pfizer leading a team in the application of human genetics and computational biology to discover and develop therapeutics and pharmacogenomics strategies in diabetes, inflammatory diseases and oncology. He is a member of the Board of Directors of Ensoma. Dr. Seymour received his undergraduate degree in Biology from the University of Delaware and M.S. degree in Molecular Biology from Johns Hopkins University, where he focused on the molecular genetics of cancer. He received his Ph.D. and post-doctoral training in human genetics at the University of Pittsburgh.